openPR Logo
Press release

ANI Pharmaceuticals to Acquire Alimera Sciences for $381 Million M&A Deal

06-27-2024 02:34 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Insidearbirage.com

Insidearbirage.com

ANI Pharmaceuticals, Inc. (ANIP) and Georgia-based biopharmaceutical company Alimera Sciences, Inc. (ALIM) on June 24, 2024, entered into a definitive agreement under which ANI will acquire Alimera for $381 million [https://www.insidearbitrage.com/2024/06/ani-pharmaceuticals-to-acquire-alimera-sciences-for-381-million/?utm_source=ABNewswire&utm_medium=Paidpr]. This strategic acquisition aims to enhance ANI Pharmaceuticals' position in the ophthalmology market, marking a noteworthy shift in its growth strategy.

Image: https://www.insidearbitrage.com/wp-content/uploads/2024/06/NMA-featured-image-template-18-2048x700.png

Deal Structure:

As per the agreement, ANI will acquire Alimera for $5.50 per share in cash, representing a premium of 74.6% from the stock's last close.

Along with the cash, Alimera shareholders will receive one non-tradable contingent value right (CVR) of up to $0.50 per share, with up to $0.25 per share for net revenues exceeding $140 million in 2026 (sliding scale-up to $150 million) and up to $0.25 per share for net revenues exceeding $160 million in 2027 (sliding scale up to $175 million).

Strategic Rationale

ANI Pharmaceuticals, known for its diversified portfolio of high-quality branded and generic pharmaceutical products, sees this acquisition as a strategic fit. Alimera Sciences, a leader in the development and commercialization of ophthalmic pharmaceuticals, brings to the table its flagship product, ILUVIEN Registered . ILUVIEN Registered is an intravitreal implant used to treat diabetic macular edema (DME) and non-infectious uveitis, expanding ANI's reach into the high-growth ophthalmology market.

Arthur Przybyl, President and CEO of ANI Pharmaceuticals, expressed his enthusiasm for the acquisition: "This acquisition aligns perfectly with our growth strategy, enhancing our portfolio with a leading ophthalmic product and expanding our footprint in a new therapeutic area. We believe this will create significant value for our shareholders and provide new opportunities for our employees."

Alimera Sciences' Perspective

Founded in 2003, Alimera Sciences has been dedicated to the development and commercialization of innovative ophthalmic treatments. Dan Myers, CEO of Alimera Sciences, commented on the acquisition: "Joining forces with ANI Pharmaceuticals is a great opportunity for Alimera Sciences. ANI's resources and expertise will enable us to accelerate the commercialization of ILUVIEN Registered and advance our pipeline of ophthalmic products. We are excited about the future prospects for our employees and customers."

Market Impact

The acquisition is expected to close in the second half of 2024, subject to regulatory approvals and customary closing conditions. Analysts predict that this deal will significantly enhance ANI Pharmaceuticals' market position, providing a solid foundation for growth in the ophthalmology sector.

Industry experts view this acquisition as a strategic move to capitalize on the growing demand for ophthalmic treatments, driven by an aging population and increasing prevalence of diabetes-related eye conditions. The global diabetic macular edema market alone is projected to reach $4.8 billion by 2026, according to a report by MarketsandMarkets.

Financial Outlook

The acquisition is anticipated to be accretive to ANI Pharmaceuticals' earnings per share (EPS) in the first year following the close. The company expects to achieve significant synergies through operational efficiencies and cross-selling opportunities.

Moreover, the deal is expected to strengthen ANI Pharmaceuticals' revenue base and enhance its R&D capabilities, providing a robust pipeline of products to drive future growth.

Deal Details and Timeline:

ANI expects this acquisition to add about $105 million in brand revenues, strengthening its Rare Disease business. Alimera's ILUVIEN and YUTIQ will add to ANI's ophthalmology segment.

Alimera's current EV/EBITDA (TTM) ratio is 21.82, above the sector median of 15.48.

The deal, expected to close late in the third quarter of 2024, will help ANI expand its reach to the European and Middle Eastern markets through Alimera's reach.

Deal Metrics:

For more details regarding this M&A transaction, please visit the Deal Metrics page here @ https://www.insidearbitrage.com/2024/06/ani-pharmaceuticals-to-acquire-alimera-sciences-for-381-million/ [https://www.insidearbitrage.com/deal-metrics/ALIM/2996/alimera-sciences-inc-to-be-acquired-by-ani-pharmaceuticals-inc/?utm_source=ABNewswire&utm_medium=Paidpr]

The Deal Metrics page for each merger or acquisition includes:

- A spread history chart of the merger from announcement through eventual completion or failure. - Every event as the merger progresses through the expiration of the HSR period, various regulatory approvals, shareholder votes, etc. - News and SEC filings. - A history of deal updates. - And a whole lot more.

About InsideArbitrage:

InsideArbitrage is a leading platform for investment insights and education, offering curated reading lists, analysis, and premium tools for investors seeking to enhance their knowledge of special situations investing that includes the strategies of merger arbitrage [https://www.insidearbitrage.com/category/merger-risk-arbitrage/?utm_source=ABNewswire&utm_medium=Paid-PR&utm_campaign=SILK-BSX], legal insider transactions, spinoffs [https://www.insidearbitrage.com/spinoffs/?utm_source=ABNewswire&utm_medium=Paid-PR&utm_campaign=SILK-BSX], management transitions, stock buybacks [https://www.insidearbitrage.com/stock-buybacks/?utm_source=ABNewswire&utm_medium=Paid-PR&utm_campaign=SILK-BSX] and SPACs.

Inside Arbitrage provides access to six different event-driven strategies to expand your investing toolbox, special situations focused tools, qualitative writeups of ideas through weekly articles, and a comprehensive monthly newsletter.

Disclaimer: This press release includes forward-looking statements within the meaning of applicable securities laws. Forward-looking statements can generally be identified by the use of words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," "will," or similar expressions. These statements are based on the current expectations and beliefs of ANI Pharmaceuticals, Inc. (ANIP) and Alimera Sciences, Inc. (ALIM) management and are subject to a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

This content does not constitute financial advice, investment advice, or any other kind of advice, and should not be relied upon as such. Readers are encouraged to conduct their own research and seek professional guidance before making any investment decisions. The completion of the transaction is subject to various conditions, including shareholder and regulatory approvals, and there can be no assurances that the transaction will be completed as described. Neither the author nor the publishing platform assumes any responsibility or liability for any errors or omissions in the content of this press release.

Media Contact
Company Name: InsideArbitrage
Contact Person: Asif Suria
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ani-pharmaceuticals-to-acquire-alimera-sciences-for-381-million-ma-deal]
Phone: +1 (541) 221-2902
Country: United States
Website: http://www.insidearbitrage.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ANI Pharmaceuticals to Acquire Alimera Sciences for $381 Million M&A Deal here

News-ID: 3555501 • Views:

More Releases from ABNewswire

Dr. Yehuda Lehrfield of The Smile Design Center Offers Expert Tips for Long-Lasting Oral Health in Owings Mills
Dr. Yehuda Lehrfield of The Smile Design Center Offers Expert Tips for Long-Last …
Dr. Yehuda Lehrfield of The Smile Design Center in Owings Mills, MD, shares expert tips for lasting oral health, emphasizing daily care, regular checkups, and the link between oral health and overall wellness. The center also specializes in personalized Dental Implants to restore missing teeth. Owings Mills, MD - Dr. Yehuda Lehrfield, founder of The Smile Design Center, is sharing expert tips on maintaining long-lasting oral health in Owings Mills, MD.
Watch Boutique USA Expands Its Curated Collection of Luxury Watches
Watch Boutique USA Expands Its Curated Collection of Luxury Watches
Image: https://www.abnewswire.com/upload/2025/10/cc76acb0ee71bad45fea031492d4d4d7.jpg Watch Boutique USA [https://watchboutiqueusa.com/], a premier destination for discerning collectors and first-time buyers alike, has expanded its exclusive selection of authentic timepieces from the world's most prestigious brands. Operating both online and by private appointment in its Miami showroom, the boutique combines trust, authenticity, and concierge-style service to provide an unparalleled buying and selling experience. A Legacy of Luxury and Trust For over a decade, Watch Boutique USA has established a
Contentus Digital Transforms India's Content Industry with SEO-Driven, Story-Powered Writing
Contentus Digital Transforms India's Content Industry with SEO-Driven, Story-Pow …
Contentus Digital, a premier content writing agency in India, is setting new benchmarks in digital communication by offering brands powerful words that connect, engage, and convert. With a proven track record of delivering SEO-optimized content for businesses across industries, the agency is revolutionizing how companies build trust, visibility, and sales through compelling storytelling. Kolkata, India - October 2, 2025 - Contentus Digital, a premier content writing agency in India, is setting
How to Save 10% on Chicago Bulls United Center Tickets Now: Use Promo Code CITY10 at CapitalCityTickets.com
How to Save 10% on Chicago Bulls United Center Tickets Now: Use Promo Code CITY1 …
Score big savings on Chicago Bulls tickets at United Center! Learn how to save 10% instantly using promo code CITY10 at CapitalCityTickets.com. Get step-by-step tips to secure the best seats for your favorite games, compare ticket options, and enjoy exclusive online discounts. Don't miss this chance to watch the Bulls live while keeping your wallet happy-grab your discounted tickets today and cheer courtside without overspending! As the crisp fall air settles

All 5 Releases


More Releases for ANI

Hayder Al-Ani launches Mission Connect to Revolutionise Global Business Communic …
London - 27 September, 2024 - Hayder Al-Ani, CEO, is proud to announce the launch of Mission Connect, a pioneering global communication agency designed to enhance companies' engagement with international audiences. This rebrand marks a new chapter in the business journey, reflecting the international growth and new services on offer. Mission Connect: Elevating Global Communication With a focus on empowering businesses to communicate more effectively across languages and borders, Mission Connect offers
Erythromelalgia Treatment Market | ANI Pharmaceuticals, Inc, AbbVie, Acorda Ther …
The global erythromelalgia treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the erythromelalgia treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth of the
Dyspnea Treatment Market | ANI Pharmaceuticals, Inc, Akorn Inc, Amneal Pharmaceu …
The global dyspnea treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the dyspnea treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth of the
Corporate Cab Service Market is Booming Worldwide | Uber, OLA (ANI Technologies, …
Advance Market Analytics published a new research publication on "Corporate Cab Service Market Insights, to 2027" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Corporate Cab Service market was mainly driven by the increasing R&D spending across the world. Get Free Exclusive PDF Sample
Moto Taxi Service Market is Booming Worldwide | Grab, Taxify, ANI Technologies
Worldwide Moto Taxi Service Market In-depth Research Report 2021, Forecast to 2026 is the latest research study released by HTF MI evaluating the market risk side analysis, highlighting opportunities, and leveraging with strategic and tactical decision-making support. The report provides information on market trends and development, growth drivers, technologies, and the changing investment structure of the Worldwide Moto Taxi Service Market. Some of the key players profiled in the study
Ride sharing Market to See Revolutionary Growth with Uber, ANI, Lyft
Advance Market Analytics released the research report of Ride sharing Market, which offers a detailed overview of the factors influencing the global business scope. Ride sharing Market research report shows the latest market insights with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Ride sharing. This Report covers the emerging player’s data, including competitive